Unusual Skin Metastasis in a Patient with Recurrent Micropapillary Serous Ovarian Carcinoma – A Case Report and Review of the Literature

The presence of skin metastasis in ovarian cancer patients is uncommon and related with poor prognosis. We report a 49-year-old patient with recurrent ovarian cancer presented with extensive skin metastasis on the anterior chest (including bilateral breast skin), lower abdomen, vulva and the upper part of the lower limbs at 21 months after initial diagnosis of ovarian cancer. The skin biopsy revealed metastasis of adenocarcinoma in the dermis. The patient underwent palliative chemotherapy and she died after 2 months of the diagnosis of the skin metastasis. It is the first case of skin metastasis from a micropapillary serous ovarian carcinoma published in Romania.

Download Full-text

Ovarian Cancer Metastasis to the Larynx: A Case Report and Review of the Literature

Case Reports in Surgery ◽

10.1155/2020/1543129 ◽

2020 ◽

Vol 2020 ◽

pp. 1-4

Author(s):

Chad Purcell ◽

Ayham Al Afif ◽

Martin Bullock ◽

Martin Corsten

Keyword(s):

Ovarian Cancer ◽

Ovarian Carcinoma ◽

World Literature ◽

Cancer Metastasis ◽

High Grade ◽

Review Of The Literature ◽

Serous Ovarian Carcinoma ◽

The World ◽

History Of ◽

Progressive Dysphagia

Laryngeal secondary malignancies are rare, and most spread locoregionally from hypopharyngeal or thyroid primaries. Metastasis of ovarian carcinoma to the larynx is extremely rare. A 65-year-old woman with a history of high grade serous ovarian carcinoma was undergoing carboplatin chemotherapy for recurrence. She presented with progressive dysphagia and hoarseness; a computer tomography (CT) scan demonstrated bilateral necrotic lymphadenopathy and hypopharyngeal fullness. A hypopharyngeal mass was confirmed on examination, and operative biopsy identified it as high-grade serous ovarian. To our knowledge, this report describes the second immunohistochemically proven metastatic ovarian cancer detected in the larynx in the world literature.

Download Full-text

Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network

Human Pathology ◽

10.1016/j.humpath.2018.10.020 ◽

2019 ◽

Vol 85 ◽

pp. 299-308 ◽

Cited By ~ 9

Author(s):

Jalid Sehouli ◽

Elena Ioana Braicu ◽

Rolf Richter ◽

Carsten Denkert ◽

Paul Jank ◽

...

Keyword(s):

Ovarian Cancer ◽

Ovarian Carcinoma ◽

Hormone Receptor ◽

Prognostic Significance ◽

Receptor Expression ◽

Low Grade ◽

Ki 67 ◽

Serous Ovarian Carcinoma ◽

Hormone Receptor Expression ◽

Cancer Network

Download Full-text

Low-grade Serous Ovarian Carcinoma

Geburtshilfe und Frauenheilkunde ◽

10.1055/a-0717-5411 ◽

2018 ◽

Vol 78 (10) ◽

pp. 972-976 ◽

Cited By ~ 7

Author(s):

Enzo Ricciardi ◽

Thaïs Baert ◽

Beyhan Ataseven ◽

Florian Heitz ◽

Sonia Prader ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Trials ◽

Ovarian Carcinoma ◽

Systemic Treatment ◽

Hormonal Treatment ◽

Current Treatment ◽

Low Grade ◽

Separate Entity ◽

Serous Ovarian Carcinoma ◽

Number Of Patients

AbstractIn the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (LGSOC) is a separate entity with a unique mutational landscape and clinical behaviour. As less than 10% of serous carcinomas of the ovary are low-grade, they are present in only a small number of patients in clinical trials for ovarian cancer. Therefore the current treatment of LGSOC is based on smaller trials, retrospective series, and subgroup analysis of large clinical trials on ovarian cancer. Surgery plays a major role in the treatment of patients with LGSOC. In the systemic treatment of LGSOC, hormonal treatment and targeted therapies seem to play an important role.

Download Full-text

GATA3 and stemness of high-grade serous ovarian carcinoma: novel hope for the deadliest type of ovarian cancer

Human Cell ◽

10.1007/s13577-020-00368-0 ◽

2020 ◽

Vol 33 (3) ◽

pp. 904-906 ◽

Cited By ~ 1

Author(s):

Amr Ahmed El-Arabey ◽

Mohnad Abdalla ◽

Adel Rashad Abd-Allah

Keyword(s):

Ovarian Cancer ◽

Ovarian Carcinoma ◽

High Grade ◽

Serous Ovarian Carcinoma

Download Full-text

Mechanisms of Chromosomal Instability in High-grade Serous Ovarian Carcinoma

10.1101/727537 ◽

2019 ◽

Cited By ~ 1

Author(s):

N. Tamura ◽

N. Shaikh ◽

D. Muliaditan ◽

J. McGuinness ◽

D. Moralli ◽

...

Keyword(s):

Ovarian Cancer ◽

Ovarian Carcinoma ◽

Single Molecule ◽

Chromosomal Instability ◽

Poor Prognosis ◽

Spindle Assembly Checkpoint ◽

Western World ◽

Cancer Type ◽

High Grade ◽

Serous Ovarian Carcinoma

AbstractChromosomal instability (CIN), the continual gain and loss of chromosomes or parts of chromosomes, occurs in the majority of cancers and confers poor prognosis. Mechanisms driving CIN remain unknown in most cancer types due to a scarcity of functional studies. High-grade serous ovarian carcinoma (HGSC), the most common subtype of ovarian cancer, is the major cause of death due to gynaecological malignancy in the Western world with chemotherapy resistance developing in almost all patients. HGSC exhibits high rates of chromosome aberrations and knowledge of causative mechanisms is likely to represent an important step towards combating the poor prognosis of this disease. However, very little is known about the nature of chromosomal instability exhibited by this cancer type in particular due to a historical lack of appropriate cell line models. Here we perform the first in-depth functional characterisation of mechanisms driving CIN in HGSC by analysing eight cell lines that accurately recapitulate HGSC genetics as defined by recent studies. We show, using a range of established functional CIN assays combined with live cell imaging and single molecule DNA fibre analysis, that multiple mechanisms co-exist to drive CIN in HGSC. These include supernumerary centrosomes, elevated microtubule dynamics and DNA replication stress. By contrast, the spindle assembly checkpoint was intact. These findings are relevant for developing therapeutic approaches to manipulating CIN in ovarian cancer, and suggests that such approaches may need to be multimodal to combat multiple co-existing CIN drivers.

Download Full-text

The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma

Communications Biology ◽

10.1038/s42003-021-02992-4 ◽

2022 ◽

Vol 5 (1) ◽

Author(s):

Hidenori Machino ◽

Syuzo Kaneko ◽

Masaaki Komatsu ◽

Noriko Ikawa ◽

Ken Asada ◽

...

Keyword(s):

Ovarian Cancer ◽

Ovarian Carcinoma ◽

Cell Cycle Progression ◽

Target Genes ◽

Metabolic Stress ◽

Ovarian Cancer Cells ◽

Hippo Signaling ◽

High Grade ◽

Gynecological Malignancy ◽

Serous Ovarian Carcinoma

AbstractHigh-grade serous ovarian carcinoma (HGSOC) is the most aggressive gynecological malignancy, resulting in approximately 70% of ovarian cancer deaths. However, it is still unclear how genetic dysregulations and biological processes generate the malignant subtype of HGSOC. Here we show that expression levels of microtubule affinity-regulating kinase 3 (MARK3) are downregulated in HGSOC, and that its downregulation significantly correlates with poor prognosis in HGSOC patients. MARK3 overexpression suppresses cell proliferation and angiogenesis of ovarian cancer cells. The LKB1-MARK3 axis is activated by metabolic stress, which leads to the phosphorylation of CDC25B and CDC25C, followed by induction of G2/M phase arrest. RNA-seq and ATAC-seq analyses indicate that MARK3 attenuates cell cycle progression and angiogenesis partly through downregulation of AP-1 and Hippo signaling target genes. The synthetic lethal therapy using metabolic stress inducers may be a promising therapeutic choice to treat the LKB1-MARK3 axis-dysregulated HGSOCs.

Download Full-text

Diagnostic accuracy of PET/CT scan in evaluation of clinically suspected recurrent ovarian cancer

Journal of Fatima Jinnah Medical University ◽

10.37018/txti8122 ◽

2021 ◽

Vol 14 (4) ◽

pp. 156-160

Author(s):

Nimrah Sultana ◽

Shaista Shoukat ◽

Sadaf Nausheen ◽

Bakhtawar Memon

Keyword(s):

Ovarian Cancer ◽

Diagnostic Accuracy ◽

Ovarian Carcinoma ◽

Ct Scan ◽

Tumor Marker ◽

Recurrent Ovarian Cancer ◽

Ca 125 ◽

Pet Ct ◽

Suspected Recurrence ◽

Pet Ct Scan

Background: Accurate evaluation of ovarian carcinoma is utmost important for effective management. PET/CT is reported to be effective in evaluation of suspected recurrence of ovarian carcinoma. This study aims to assess the accuracy of PET/CT in evaluation of recurrent ovarian cancer among clinically suspected cases with rising tumor marker or suspicious clinic-radiological findings. Patients and methods: This prospective cross-sectional study was conducted at Radiology department of Jinnah Postgraduate Medical Centre Karachi from 22nd April 2019 to 21st April 2020. Patients having age of 40 to 60 years and referred for PET scan with suspected recurrence of ovarian carcinoma were consecutively enrolled. Patients were suspected due to relevant history, clinical findings and initial imaging investigations with elevated CA-125 level. Results of 18FDG PET/CT scan was correlated with the raised tumor findings. The PET/CT scan showing abnormally elevated FDG take-up and higher SUV values than the background activity considered recurrence. Diagnostic accuracy of PET/CT was calculated taking raised tumor level as reference category. Results: Of 65 patients, median age was 50 (43-56) years. The findings showed positive cases in 57 (87.7%) while negative in 8 (12.3%) patients, whereas the findings of tumor marker showed raised tumor marker in 61 (93.8%) patients. Diagnostic accuracy of PET/CT showed sensitivity, specificity, positive predicted value, negative predated value, and overall diagnostic accuracy as 93.44%, 100%, 100%, 50%, and 93.85% respectively. Conclusion: A higher accuracy of PET/CT was observed in the diagnosis of recurrent ovarian cancer among clinically suspected cases, thus helping in devising an appropriate management plan by the treating physician.

Download Full-text

Circulating tumor DNA analysis to reveal genomic profiles for epithelial ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.5543 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. 5543-5543

Author(s):

Yang Xiang ◽

Shan Zhu ◽

Weiran Wang ◽

Dongyan Cao ◽

Xi-Run Wan ◽

...

Keyword(s):

Ovarian Cancer ◽

Ovarian Carcinoma ◽

Epithelial Ovarian Cancer ◽

Circulating Tumor Dna ◽

Stage Iii ◽

Signal Pathways ◽

Low Grade ◽

Serous Ovarian Carcinoma ◽

Ctdna Analysis ◽

Tumor Dna

5543 Background: Circulating tumor DNA (ctDNA) analysis in epithelial ovarian cancer (EOC) was previously reported, however with limited samples or limited genes. Here, we reported an analysis of ctDNA in EOC cohort using targeted sequencing with a 1021-gene panel. Methods: Patients with EOC were enrolled, and treatment-naïve tumor tissues and blood samples were collected. We utilized a 1021-gene NGS panel in matched tissue DNA and ctDNA to identify somatic mutations with white blood cell DNA as a germline control. Results: Mutations were identified in all of the 65 tissues and in 53 (81.5%) ctDNA. The median ctDNA mutation allelic frequency was 2.5%, ranging from 0.1% to 36.2%. A median of 66.7% (12.5%-100.0%) of tissue derived mutations were observed in ctDNA. Besides, there were 91 ctDNA private mutations, including TP53 gene mutations. The most frequently mutated genes were TP53 (55.4%), PIK3CA (13.8%) and ARID1A (12.3%) in ctDNA analysis, which were consistent with tissue analysis (60.0%, 26.2% and 20.0% of tissues with TP53, PIK3CA and ARID1A mutations, respectively). Mutations of TP53 (37/42) in high-grade serous ovarian carcinoma (HGSOC), PIK3CA (10/11) and ARID1A (8/11) in ovarian clear cell carcinoma, BRAF (4/5) in low-grade serous ovarian carcinoma and PIK3CA (3/5), ARID1A (2/5) and PTEN (2/5) in endometrioid carcinoma were observed as the most commonly genetic aberrations in ctDNA in different sub-types of EOC, which located in different signal pathways and suggested different pathogenesis. In total, 90.5% (38/42) of HGSOC were ctDNA positive, comparing with 65.2% (15/23) of other EOC subtypes (p = 0.012). In addition, 56.5% (13/23) of stage I~II EOC were ctDNA positive, comparing with 94.7% (36/38) of stage III (p = 0.002). No association between ctDNA positivity and other clinic characteristics was observed, including pathological differentiation, CA125, lesion density (solid vs. cystic-solid and cystic). Multivariable analysis suggested FIGO stage III (p = 0.008) as an independent predictor of ctDNA detection. Conclusions: In summary, genomic characterization of EOC may offer insights into tumorigenesis and identify potential therapeutic targets in this disease.

Download Full-text